Forte Biosciences (FBRX) Retained Earnings (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Retained Earnings of -$245.5 million for Q1 2026, down 44.71% year-over-year from -$444.0 million in Q1 2025, and down 9.91% quarter-over-quarter from -$223.4 million in Q4 2025.
Forte Biosciences (FBRX) Retained Earnings (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Retained Earnings for 11 consecutive years, with -$245.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 44.71% year-over-year to -$245.5 million; the TTM figure through Mar 2026 stood at -$245.5 million (down 44.71% YoY), while the FY2025 annual figure was -$223.4 million, down 45.05% from the prior year.
- Retained Earnings retreated to -$245.5 million in Q1 2026 per FBRX's latest filing, from -$223.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$6000.0 in Q3 2025 and bottomed at -$245.5 million in Q1 2026.
- Historically, Retained Earnings has averaged -$117.5 million across 5 years, with a median of -$112.6 million in 2023.
- On a YoY basis, Retained Earnings climbed as much as 100.0% in 2025 and fell as far as 2584228.57% in 2025.
- Forte Biosciences' Retained Earnings stood at -$87.0 million in 2022, then plunged by 36.16% to -$118.5 million in 2023, then slipped by 29.93% to -$154.0 million in 2024, then plunged by 45.05% to -$223.4 million in 2025, then retreated by 9.91% to -$245.5 million in 2026.
- Business Quant data shows FBRX's Retained Earnings at -$245.5 million in Q1 2026, -$223.4 million in Q4 2025, and -$6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -268.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -268.84 Mn |
| Mar 31, 2026 | -245.50 Mn |
| Dec 31, 2025 | -223.37 Mn |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -180.90 Mn |
| Mar 31, 2025 | -169.65 Mn |
| Dec 31, 2024 | -154.00 Mn |
| Sep 30, 2024 | -146.80 Mn |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | -125.94 Mn |
| Dec 31, 2023 | -118.52 Mn |
| Sep 30, 2023 | -112.65 Mn |
| Jun 30, 2023 | -102.69 Mn |
| Mar 31, 2023 | -93.80 Mn |
| Dec 31, 2022 | -87.04 Mn |
| Sep 30, 2022 | -82.20 Mn |
| Jun 30, 2022 | -78.77 Mn |
| Mar 31, 2022 | -75.70 Mn |
| Dec 31, 2021 | -73.17 Mn |
| Sep 30, 2021 | -69.80 Mn |